Medicilon’s Antibody-Peptide Conjugates Service Platform
Therapeutic peptides are a rapidly expanding class of medicines, driven by the success of long-acting incretin therapies. However, natural peptides face limitations due to rapid degradation, kidney clearance, and short plasma half-lives. Traditional strategies involve chemical modification (e.g., lipid conjugation, cyclization, unnatural amino acids) or genetic engineering (e.g., Fc, albumin fusion proteins). While fusion proteins […]
ACEA Pharma’s Ogrelvir Sodium Capsule Named in Nature’s 2025 Top Novel Target Drugs List with R&D Support from Medicilon
Recently, ACEA Pharma has announced that Ogrelvir Sodium Capsule (brand name: Oveinin®), its independently developed oral antiviral agent, has been selected to the Nature Reviews Drug Discovery 2025 Top Novel Target Drugs List. This achievement marks the first time a Chinese innovative drug has earned a spot on this globally recognized authoritative ranking. Medicilon, a […]
Medicilon Supports Partner Nanolattix, Two RDC and ADC Studies Accepted for EANM’26; HER2/TF Bispecific Research Selected as Top-Rated Oral Presentation
Two studies from Nanolattix Group have been accepted for the 2026 Annual Congress of the European Association of Nuclear Medicine (EANM’26). Among them, “Novel Bispecific RDC+ADC Theranostics Targeting HER2 & TF” has been selected for a Top Rated Oral Presentation (TROP). EANM’26 will take place in Vienna, Austria, from October 17 to 21. As Nanolattix’s […]
Powering Another GLP‑1/GIP Dual Receptor Agonist for Global Expansion! Medicilon Congratulates Hengrui Pharma on Exclusive License Agreement with Novo Nordisk for HRS‑1596
Hengrui Pharma (600276.SH; 01276.HK) recently announced that it has entered into a license agreement with Novo Nordisk for HRS‑1596. HRS‑1596 is a GLP‑1/GIP dual receptor agonist ready for Phase I clinical trials, with potential for once‑weekly oral administration. As the preclinical research partner for HRS‑1596, Medicilon provided pharmacokinetic and safety evaluation services to support the […]
Medicilon Congratulates : MindRank AI-Developed Oral GLP-1 MDR-001 Secures Up to RMB 1.75 Billion Exclusive Commercialization Deal with Sunshine Mandi
September 28 — MindRank AI Ltd. (“MindRank”) today announced that it has entered into a strategic commercialization agreement with Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. (“Sunshine Mandi”) and Zhejiang Wansheng Pharmaceutical Co., Ltd. (“Wansheng”), both subsidiaries of 3SBio Inc. (01530.HK) group, for MDR-001, an AI-designed oral small-molecule GLP-1 receptor agonist in a pivotal Phase 3 […]
A Note of Appreciation, A Mark of Recognition | Medicilon Supports Partner Tasly in Obtaining Clinical Trial Approval for TSL2402 Tablets
Recently, Tianjin Tasly Saint Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Tasly Pharmaceutical Group Co., Ltd. (Stock Code: 600535), received the Notice of Approval for Drug Clinical Trial (No. 2026LP02559) for TSL2402 Tablets issued by the National Medical Products Administration (NMPA), authorizing the initiation of clinical trials for the drug.As Tasly’s partner, Medicilon has received […]
【BRIDGE】Medicilon XDC Innovation Forum · Seoul 2026
Medicilon successfully hosted the BRIDGE | Medicilon XDC Innovation Forum · Seoul 2026 in Seoul, Korea, on September 10, 2026. The forum united Chinese and Korean XDC experts, scholars, and industry leaders who shared insights, practical experience, and innovative strategies to accelerate XDC drug development through solution-focused presentations. Opening Remarks : Medicilon XDC Innovation Forum Dr. Maosheng DuanPresident of […]
Medicilon’s Formulation CDMO Platform Advances Taiji Group’s Next-Generation RNA Polymerase Inhibitor DSC158A Tablets to Clinical Stage
Chongqing Fuling Pharmaceutical Factory Co., Ltd., a wholly-owned subsidiary of Chongqing Taiji Industry (Group) Co., Ltd., has received the Clinical Trial Approval Notice for DSC158A Tablets from the National Medical Products Administration (NMPA). A next-generation RNA polymerase inhibitor, DSC158A Tablets are developed for the treatment of influenza A and influenza B in adult patients. As […]
TPD CN-US Dual Filing Milestone: Medicilon’s One-Stop Platform Helps Gluetacs Secure Dual Approval for GT818, a First-in-Class RSK Degrader
August 31, 2026 —Gluetacs Therapeutics announced that GT818 capsules, its self-developed first-in-class innovative drug, has been approved by the U.S. Food and Drug Administration (FDA) to enter clinical trials for the treatment of advanced malignant tumors. The candidate previously received an implied clinical trial approval from China’s National Medical Products Administration (NMPA) on July 1, […]
World’s First Long-Acting Anti-RSV Monoclonal Antibody Xinduotuo Wins NMPA Approval — Medicilon Empower Trinomab’s Source Innovation
September 3, 2026 — The world’s first fully human long-acting anti-RSV monoclonal antibody, Xinduotuo (generic name: retavibart injection; development code: TNM001), independently developed by Zhuhai Trinomab Pharmaceutical Co., Ltd. (STAR Market: 688806, “Trinomab”), has received marketing approval from China’s National Medical Products Administration (NMPA). It is indicated for the prevention of RSV-associated lower respiratory tract […]
